Models of myeloma bone disease: In vivo and in vitro approaches
Bone · 2026
DOI: 10.1016/j.bone.2026.117789 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Bone, 2026. Verfasst von Jiaxian Wang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Amsterdam UMC - location Vrije Universiteit Amsterdam, Amsterdam, the Netherlands; Cancer Center Amsterdam, Cancer Biology …. Hauptthemen laut MEDLINE: Multiple Myeloma, Bone Diseases, Models, Biological. Die Arbeit nennt 170 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: China Scholarship Council, Central People's Government of the People's Republic of China Scholarship Programme, Dutch Cancer Society.
Abstract (Originalsprache)
This review focuses on experimental models developed to study myeloma bone disease (MBD), a major cause of morbidity in multiple myeloma (MM). Under physiological conditions, bone remodeling is regulated by osteoclasts (OCs) and osteoblasts (OBs); in MM, this balance is disrupted, resulting in enhanced bone resorption and suppressed bone formation. Myeloma cells alter the bone marrow (BM) microenvironment by increasing the RANKL/OPG ratio and secreting Wnt pathway inhibitors such as DKK-1 and sclerostin, thereby promoting osteoclastogenesis and inhibiting osteoblast differentiation. To dissect these mechanisms and evaluate therapeutic strategies, diverse preclinical systems have been developed. Syngeneic murine models, notably the 5T series, remain the most established for reproducing both osteolysis and impaired bone formation, though interspecies differences limit translational relevance. Humanized mouse systems and three-dimensional (3D) in vitro models increasingly address these constraints by incorporating human stromal and hematopoietic elements. Emerging induced pluripotent stem cell-derived bone marrow organoids (iBMOs) offer a fully human platform capable of modeling both osteoclast and osteoblast dynamics. While current iBMOs lack mineralized bone and mature vascular or immune components, advances in differentiation control and matrix engineering are expected to bridge these gaps, providing physiologically relevant and ethically sustainable models for studying MBD and testing therapeutic interventions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hematology, Amsterdam UMC - location Vrije Universiteit Amsterdam, Amsterdam, the Netherlands; Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam, the Netherlands.
- Department of Hematology, Amsterdam UMC - location Vrije Universiteit Amsterdam, Amsterdam, the Netherlands; Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam, the Netherlands; Amsterdam Movement Science…
Förderung
- China Scholarship Council
- Central People's Government of the People's Republic of China Scholarship Programme
- Dutch Cancer Society
Zitieren
APA
Wang, J., Zweegman, S., & Groen, R. W. J. (2026). Models of myeloma bone disease: In vivo and in vitro approaches. Bone. https://doi.org/10.1016/j.bone.2026.117789
Vancouver
Wang J, Zweegman S, Groen RWJ. Models of myeloma bone disease: In vivo and in vitro approaches. Bone. 2026. doi:10.1016/j.bone.2026.117789
BibTeX
@article{Wang2026,
author = {Wang, Jiaxian and Zweegman, Sonja and Groen, Richard W J},
title = {Models of myeloma bone disease: In vivo and in vitro approaches},
journal = {Bone},
year = {2026},
doi = {10.1016/j.bone.2026.117789}
}
EUVIMED